Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27600495 | 0.81 | ALDH1A1 (0.50) | GAAMAPTNPSR1LMNAKDM4E | |
| SCHEMBL31440040 | 0.79 | GAA (0.46) | GAAMAPTNPSR1LMNAKDM4E | |
| SCHEMBL27041924 | 0.79 | GAA (0.46) | GAAMAPTNPSR1LMNAKDM4E | |
| SCHEMBL6286816 | 0.79 | GAA (0.46) | GAAMAPTNPSR1LMNAKDM4E | |
| SCHEMBL16652388 | 0.79 | GAA (0.46) | GAAMAPTNPSR1LMNAKDM4E | |
| SCHEMBL29613215 | 0.75 | GAA (1.00) | GAAMAPTTSHRALDH1A1NPC1 | |
| SCHEMBL3752114 | 0.75 | GAA (1.00) | GAAMAPTTSHRALDH1A1NPC1 | |
| SCHEMBL173611 | 0.74 | GAA (0.62) | GAAMAPTNPSR1LMNAKDM4E | |
| SCHEMBL11710730 | 0.71 | CYP2A6 (0.43) | GAAMAPTALDH1A1RAB9AMEN1 | |
| SCHEMBL7559094 | 0.69 | HTR7 (0.45) | GAAMAPTNPSR1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534799-B2 | Pyridomorphinans, thienomorphinans and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2009-05-19 | — | — | US | disclosed |
| US-20060264452-A1 | Pyridomorphinans, thienomorphinans and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2006-11-23 | — | — | US | disclosed |
| US-7105675-B2 | Pyridomorphinans, thienomorphinans and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2006-09-12 | — | — | US | disclosed |
| US-7015326-B1 | Pyridomorphinans, thienomorphinans and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060047119-A1 | Pyridomorphinans, thienomorphinans and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2006-03-02 | — | — | US | disclosed |
| US-6762192-B2 | USEFUL IN THERAPY AND PROPHYLAXIS OF EPILEPSY, MIGRAINE, AND OTHER DISORDERS | SMITHKLINE BEECHUM P.L.C. (GB) | 2004-07-13 | — | — | US | disclosed |
| EP-1084122-B1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| US-6245778-B1 | 1,6-naphthyridine anti-convulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264452-A1 | Pyridomorphinans, thienomorphinans and use thereof | OPRL1, OPRM1, OPRK1 | GAA 4260/4885MAPT 4107/4885NPSR1 105/4885 |
| US-20060047119-A1 | Pyridomorphinans, thienomorphinans and use thereof | OPRL1, OPRM1, OPRK1 | GAA 4260/4885MAPT 4107/4885NPSR1 105/4885 |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | CNR1, SCN1B, CNR2 | GAA 4585/4885MAPT 2605/4885NPSR1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.